

MArS Webinar:

The new one in the German Ministry of Health? All the same or significant changes?

27th January 2022

Dr. Stefan Walzer Lutz Vollmer

MArS Market Access & Pricing Strategy GmbH, Germany
State University Baden-Wuerttemberg, Germany
University of Applied Sciences Ravensburg-Weingarten, Germany

THE German-speaking market access experts - Austria, Germany, Switzerland











The first and only Market Access Podcast by MArS




https://marketaccess-pricingstrategy.de/en/map-podcast/









Did you hear our MAP-Podcast already?

MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy.







February episodes






Questions welcome!




• Feel free to ask questions. After the presentation, we will have time for your questions.

 Use either the Zoom chat function or the Q&A function to raise your questions or comments.

• As always, slides will be provided afterwards, and the video will be published on our website.









Our presenters and discussants today





Dr. Stefan Walzer Speaker



Lutz Vollmer Moderator







MArS Webinar:

The new one in the German Ministry of Health? All the same or significant changes?

Social democrats won the elections in autumn 2022 in Germany







Germany has a new government since December 2022








https://www.pro-medienmagazin.de/so-wahr-mir-gott-helfe-so-legten-die-ampelminister-den-amtseid-ab/

Source: Bundesregierung/Denzel – from https://www.bundesregierung.de/breq-de/mediathek/fotos?page=1

Former minister of health actively changing the (market access) environment





"You" wanted him, you'll get him?





Who is the new one? Prof. Dr. Lauterbach



So, how would Prof. Lauterbach describe himself?



Probably not "the normal one"



Who is the new one? Prof. Dr. Lauterbach





Prof. Dr. Dr. Karl Lauterbach SPD the new minister of health

- 21.02.1963 born
- Study of medicine and doctorate (Dr. med)
- Study of health economics and epidemiology
- Doctorate (Dr.sc) Harvard University
- University Professor, Director of the Institute of Health Economics and Clinical Epidemiology (University of Cologne) since 1998, on leave since 11/2005
- Since 2008 Adjunct Professor at the Harvard School of Public Health in Boston
- Since 2005 Member of the Bundestag and since 2009 Health Spokesman of the SPD Parliamentary Group in the Bundestag

What impact do we expect on market access?



Given various negative effects on tax income...







... stakeholders expect an entry into force of a savings law!!

Changes already included in the coalition agreement



 Increase of mandatory rebate for drugs from 9% to 16%*

 Free pricing of drug within the AMNOG process until month 6 – paybacks starting month 7 (launch price vs reimbursement amount)



Further expected changes





 Merging of DiGA and DiPA systems for "listing", benefit assessment and reimbursement pricing.



 Potential changes in the financing of hospital investments -> Impact on medical devices open

 No changes expected with respect to reimbursement processes for medical devices.

Our guest tonight: Prof. Dr. Breisach





- Prof. Dr. Thomas Breisach looks back on more than 25 years of professional experience in the media, international groups and consultancies (including F. Hoffmann-La Roche, Novozymes MCG Medical Consulting Group).
- He has been the owner of Breisach Consulting since 2012.
- The advocate of strategic pragmatism is Professor of Health and Social Management at the FOM University of Applied Sciences in Munich.
- Within the framework of the Institute for Health and Social Affairs, his research focuses on:
 - 1. Strategy development
 - 2. Communication and marketing
 - 3. Pharmaceuticals and ingredients (e.g. micronutrients)
 - 4. International nutrition and health policy & economics

Time for questions ...



The new one in the German Ministry of Health? All the same or significant changes?



Market Access & Pricing Strategy GmbH



Dr. Stefan Walzer Speaker



Lutz Vollmer Moderator



Prof. Dr. Thomas Breisach
FOM University

Recording available on our Youtube channel via www.marketaccess-pricingstrategy.de

Register already now for our next webinar!











Dr. Renato Dellamano Value Vector & MME Europe

24.02.2022

Pricing Strategy
Art or science?



Dr. Stefano Capri Harald Herholz

Universita Cattanea KV Hessen

31.03.2022

2 years Covid-19 clinical and financial implications



Dr. med. Markus Thalheimer Universitätsklinikum Heidelberg

28.04.2022

Hospital funding 6 months before NUB deadline

at 9pm CET / 12am PT